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Background and purpose: Aggregates of the protein amyloid-beta (Ab) play a crucial role in the pathogenesis of Alzheimer’s
disease (AD). Most therapeutic approaches to AD do not target Ab, so determination of the factor(s) that facilitate aggregation
and discovering agents that prevent aggregation have great potential therapeutic value.
Experimental approach: We investigated ex vivo the temperature-sensitive regions of Ab1–40 (Ab40) and their interactions
with octapeptides derived from sequences within Ab40 – b-sheet breaker peptides (bSBP) – using enzyme-linked immunosor-
bent assay, and dot blot and far-UV circular dichroism (CD) spectroscopy. We measured changes within the physiological limits
of temperature, using antibodies targeting epitopes 1–7, 5–10, 9–14 and 17–21 within Ab40.
Key results: Temperature-dependent conformational changes were observed in Ab40 at epitopes 9–14 and 17–21 at 36–38
and 36–40°C respectively. The bSBPs 16–23 and 17–24, but not 15–22 and 18–25, could inhibit the changes. Moreover, bSBPs
16–23 and 17–24 increased digestion of Ab40 by protease K, indicating a decreased aggregation of Ab40, whereas bSBPs
15–22 and 18–25 did not increase this digestion. CD spectra revealed that b-sheet formation in Ab40 at 38°C was reduced with
bSBPs 16–23 and 17–24.
Conclusions and implications: The epitopes 9–14 and 17–21 are the temperature-sensitive regions within Ab40. The bSBPs,
Ab16–23 and 17–24 reversed temperature-induced b-sheet formation, and decreased Ab40 aggregation. The results suggest
that the 17–23 epitope of Ab40 is crucially involved in preventing Ab40 aggregation and consequent deposition of Ab40 in AD
brain.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder char-
acterized by cognitive impairment. The hallmark of AD
pathogenesis in brain is amyloid plaques composed mainly of
amyloid-beta (Ab) protein aggregates (Katzman and Saitoh,
1991). It is believed that b-sheet formation is the general
mechanism of aberrant protein aggregation leading to AD
(Walsh et al., 1999). Specific sequences within the main Ab
structure are involved in the structural transformation and
the toxic effects of Ab (Simmons et al., 1994). The hydropho-
bic core around residues 17–20 of Ab1–40 (Ab40) (Lui et al.,
2004), and protein misfolding process in which intermolecu-
lar b-sheet interactions become stabilized abnormally (Huang
et al., 2000; McAllister et al., 2005) are crucial for the forma-
tion of the b-sheet structure. Moreover, C-terminal fragments
are more harmful than N-terminal fragments of Ab, and may
induce the development of dystrophic neurites by a toxic
effect rather than by physical injury (Lin et al., 2001; Kasa
et al., 2003). Recent reports suggested that soluble Ab oligo-
mers extracted directly from AD brain potentially impair syn-
aptic structure and function, and that the Ab N-terminus is
the key sequence causing the cognitive impairment; however,
insoluble Ab did not impair the synaptic function (Cleary
et al., 2005; Shankar et al., 2008).
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The structural form of Ab is influenced by a variety of
intrinsic, as well as extrinsic, factors that cause conforma-
tional transition of Ab from a random-coil to the predomi-
nantly b-sheet structure. These factors include peptide
concentration (Barrow et al., 1992), low pH (Matsunaga et al.,
2002; Petkova et al., 2004), metal ions (Drago et al., 2007),
high cholesterol (Kakio et al., 2001; Yanagisawa and Mat-
suzaki, 2002) and pressure (Lin et al., 2002). Moreover,
temperature-dependent transition of Ab40 plays an important
role in the structural transformation from a-helix and
random-coil to b-sheet form in aqueous solution by heating
above 37°C (Gursky and Aleshkov, 2000) or at 45°C (Lin et al.,
2003).
The available drugs used in the treatment of AD mainly aim
at increasing the cholinergic activity of the remaining healthy
neurons, but do not act on the main cause of the disease. One
of the therapeutic approaches was vaccination against the
N- and C-terminals of Ab. Passive immunization against
the C-terminal increased brain-soluble Ab42/43, decreased
insoluble Ab40 and Ab42/43 and reduced plaque formation
(Asami-Odaka et al., 2005). However, the appearance of severe
side effects during clinical trials has highlighted the need for
improved safety and efficacy. In addition, low levels of anti-Ab
antibodies can be detected in individuals with or without AD,
and their presence or levels are not correlated with the like-
lihood of developing dementia (Hyman et al., 2001).
Accordingly, safer compounds preventing and reversing
cerebral deposition of Ab, and thus lowering the burden of
insoluble Ab have become an attractive therapeutic strategy
for AD. It has been found that Ab aggregation can be selec-
tively inhibited with short synthetic peptides designed as
b-sheet breaker peptides (bSBPs) (Synder et al., 1994). In vitro
cell culture and in vivo results suggest that bSBPs might be
candidates for AD therapy directed towards reducing amyloid
deposition (Permanne et al., 2002a). Two pentapeptide bSBPs
have been synthesized. One contains the same sequence as
residues 16–20 (KLVFF) within Ab (Tjernberg et al., 1996), and
the other is a five-residue synthetic peptide (iAb5: LPFFD)
homologous to the central hydrophobic fragment of Ab
17–21 (LVFFA) with substitution of P for V, and D for A (Soto
et al., 1996). Both bSBP 16–20 and 17–21 could inhibit Ab
fibrillogenesis (Hetenyi et al., 2002). Further, the bSBP 17–21
could prevent b-sheet formation, inhibit and disassemble
amyloid fibrils in vitro and also prevent Ab neurotoxicity in
cell culture (Soto et al., 1998) by stabilizing the normal con-
formation and destabilizing the b-sheet-rich structure (Soto
et al., 2000), reversing pre-existing Ab fibrils (Sigurdsson et al.,
2000) or preventing formation of the amyloid plaques (Per-
manne et al., 2002a). An end-protected version of iAb5, acety-
lated at the N-terminus and amidated at the C-terminus
(iAb5p) with high rate of penetration across the blood–brain
barrier had been synthesized. It has been reported that iAb5 is
able to induce a dramatic reduction in amyloid deposition
and the associated brain inflammation, and increase neuronal
survival (Permanne et al., 2002b).
The present study aimed at detecting temperature-sensitive
regions within Ab40, and determining whether or not
temperature-induced changes are inhibited or reversed by
octapeptide bSBPs (corresponding to residues 15–22, 16–23,
17–24 and 18–25 in Ab40) using enzyme-linked immunosor-
bent assay (ELISA), Western dot blots and far-UV circular
dichroism (CD) spectra analysis.
Methods
Temperature modification of Ab peptides and ELISA assay
ELISA was conducted for both Ab40 alone and its mixture with
bSBPs. Samples of Ab40 alone (10 mg·mL-1) were incubated
from 35 to 42°C with 1°C intervals, and also incubated at
20°C as a control for soluble Ab40, for 30 min in tubes, then
50 mL of each solution was bound to the wells of the flat
bottom high polystyrene microtitre plates overnight at the
same temperature at which it had been incubated. In a similar
way, Ab40 (10 mg·mL-1) was also incubated after mixing with
10 mg·mL-1 of each bSBP: Ab15–22, 16–23, 17–21 and 18–25.
After the removal of excess samples, the wells were first incu-
bated for 2 h with Tris-buffered saline (TBS; 20 mM Tris/
34 mM NaCl, pH 7.4) containing 3% bovine serum albumin
(BSA) at 37°C. After discarding the solution, primary antibody
(50 mL of 1 mg·mL-1 of either 4G8, 6F/3D, anti 5–10 or anti
1–7) in TBS containing 1% BSA was incubated for a further 2 h
at 37°C, pH 7.4. After incubation, the wells were washed with
TBS with 0.1% Tween-20, pH 7.4 (TBST), and incubated for an
additional 1 h at 37°C with 50 mL of a 1:5000 dilution of
alkaline phosphatase-conjugated secondary antibody. After
washing with TBST, bound antibodies were detected by the
addition of p-nitrophenyl phosphate, and the absorbance was
measured after 30 min at 405 nm using a spectrophotometric
plate reader (Microplate reader MPR A4I, Tosoh, Tokyo,
Japan). All washing steps were performed six times. The same
procedure was applied for Ab40 and bSBP mixtures.
Dot blot
A preliminary investigation was conducted using bSBPs at 1,
5, 10, 15 and 20 mg·mL-1 concentrations, and showed that
bSBP at 10–20 mg·mL-1 produced dark spots, indicating that
high amounts of protein remain on the membrane and the
spots were completely digested with protease K (PK) at
0.05 mg·mL-1. Accordingly, we carried out dot blot studies
on Ab40 at 8 mg·mL-1 with or without bSBPs at 20 mg·mL-1,
which corresponds to a molar ratio of 1:12, Ab40 : bSBP.
Temperature-modified mixtures of Ab40 and bBSP (200 mL) or
Ab40 alone at 20°C as a control for soluble Ab40 were spotted
and blotted onto methanol-immersed PVDF membrane
(0.2 mm pore size; Invitrogen, Carlsbad, CA, USA) using the
dot-blot apparatus (DP-48 Dot Plate; Advantec, Tokyo, Japan)
by absorption with a vacuum pump. The membrane was then
removed, rinsed in phosphate-buffered saline (PBS) and
digested with PK.
PK digestion and dot blots
Each membrane was incubated without and with 10 mL of PK
solution (0.05 mg·mL-1 in PBS, pH 7.4) for 1 h at 37°C with
constant shaking. After removal of the PK solution, the reac-
tion was terminated by washing with PBS with 0.1% Tween-
20, pH 7.4 (PBST) three times at 15 min intervals. After
blocking with 3% non-fat milk for 2 h, the membrane was
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again washed with PBST and allowed to react with primary
antibody 6E10 (1:10 000 dilution in PBS) for 2 h at room
temperature, then the secondary antibody peroxidase-linked
anti-mouse IgG (1:5000 dilution in PBS) was added and
allowed to react for 1 h at room temperature. The membrane
was washed three times with PBST, and the spots were
detected with enhanced chemiluminescence (Immobilon,
Western Chemiluminescent HRP substrate, Millipore Corp.,
Bedford, MA, USA) according to the manufacturer’s
instructions.
CD spectroscopy analysis
CD spectra were measured using a J-725 CD spectrometer
(JASCO, Tokyo, Japan). For the far-UV CD spectra, 1 mm path
length quartz cell (300 mL internal volume) was used, with
bandwidth of 1 nm. Ab40 was dissolved in 5 mM Tris-buffer
(pH 9) at 1 mM, and diluted 20-fold by pure water to a final
concentration of 50 mM (Bartolini et al., 2007). The bSBPs of
Ab15–22, 16–23, 17–24 and 18–25 were dissolved in 0.4 M
NaOH at 1 mM, and adjusted with HCl to pH 7 and diluted by
pure water into the same final concentration (50 mM). The
mixture of Ab40 and bSBP at 1:1 mole ratio or Ab40 alone was
incubated at 38 and 20°C as a control of soluble Ab40 for
30 min, and spectra were recorded, using 2 nm step and a 1 s
averaging time and 100 nm min-1 scan speed.
Statistical analyses
For ELISA measurement, values are presented as mean  SEM
of six experiments, each in triplicate. Differences between
6F/3D antibody and other antibodies at each temperature
were analysed using unpaired t-tests. Data of bSBPs are also
presented as mean  SEM of six experiments in triplicate, and
the differences between each (bSBP and Ab) mixture and Ab40
alone were analysed using unpaired t-tests. The values of pixel
densities from the dot blot studies at 38°C were expressed as
mean  SEM of six experiments, and statistical analysis was
by analysis of variance.
Materials
Ab peptides and bSBPs. Ab40, DAEFRHDSGYEVHHQKLVF-
FAEDVGSNKGAIIGLMVGGVV were purchased from AnaSpec
(San Jose, CA, USA) and dissolved in water as a stock solution,
and diluted with PBS, pH 7.3, to the indicated concentrations,
and used for ELISA and dot blot study. For CD study, PBS
interferes with CD spectra, and we diluted the stock Ab40
with pure water. The bSBPs: Ab15–22, 16–23, 17–24 and 18–25
were purchased from Wako (Tokyo, Japan). All bSBPs were
dissolved in a minimal amount of dimethylsulphoxide
(DMSO) for ELISA and dot blot study, or dissolved in NaOH
(0.4 M) for CD spectra analysis before dilution with water at
the indicated concentrations.
Monoclonal and polyclonal antibodies. The monoclonal anti-
bodies used were 4G8, epitope 17–21 (Signet Pathology
Systems, Inc., Dedham, MA, USA); 6F/3D, epitope 9–14
(DAKO, Glostrup, Denmark); anti 5–10, epitope 5–10 (QCB,
Camarillo, CA, USA); and 6E10, epitope 3–8 (COVANCE,
Berkeley, CA, USA). The polyclonal anti 1–7 was from QCB.
Alkaline phosphatase-conjugated goat anti-mouse IgG for
monoclonal antibody and anti-rabbit IgG for polyclonal anti-
body (Promega, Madison, WI, USA) in ELISA, and peroxidase-
labelled anti-mouse IgG (Amersham Life Science, Pharmacia
Biotech, Uppsala, Sweden) for dot blots were used as second-
ary antibody respectively.
Chemicals
BSA and p-nitrophenyl phosphate (Sigma, St Louis, MO, USA),
PK (Wako) were used. Other chemicals were from Sigma-
Aldrich (Tokyo, Japan).
Results
Reactivity of antibodies against temperature-modified Ab40
In order to determine whether the temperature was signifi-
cant in the ELISA after immobilization of Ab peptides, the OD
was measured as a function of temperature at 36, 37, 40 and
42°C with primary antibody for 2 h and secondary antibody
for 1 h. After immobilization, the samples were unaffected by
the changes to 37°C, but it also showed a corresponding slight
increase of OD by 0.03–0.04 in signal if it was incubated at
42°C (data not shown). We confirmed that the conforma-
tional changes induced by overnight incubation are preserved
after immobilization in the plates.
The antibodies investigated in this study displayed a differ-
ent reactivity against temperature-modified Ab40 (Figure 1).
No obvious differences were detected between control
samples at 20 and 35°C. A significant difference was detected
among the antibodies (P < 0.001). Moreover, the effect of each
antibody was significantly different at various temperatures
(P < 0.05). However, the antibodies–temperature interactions
did not reach significance, suggesting that the effects of
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Figure 1 Enzyme-linked immunosorbent assay (ELISA) measure-
ments of antibody affinity towards temperature-modified Ab40. The
reactivities of four antibodies (4G8, 6F/3D, anti 1–7, anti 5–10) to
samples of Ab40 that had been exposed to temperatures over the
range 36–42°C at 1°C interval and at 20°C as a control, were moni-
tored by ELISA. Statistical comparisons were performed with unpaired
t-tests. The values are means  SEM. Statistically significant differ-
ences versus 6F/3D were determined at each temperature. *P < 0.05,
**P < 0.01 (n = 6).
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different antibodies were similarly affected by various tem-
peratures. The anti 1–7 polyclonal antibody exhibited the
lowest reactivity against temperature-modified Ab40, and this
reactivity was significantly different from the other antibod-
ies. The monoclonal anti 5–10 antibody showed high levels of
reactivity compared with antibodies 6F/3D (anti 9–14) and
anti 1–7, but not from 4G8 (anti 17–21). For both anti 5–10
and 1–7 antibodies, the reactivity was constant through the
whole temperature ranges (35–42°C), and no temperature-
dependent difference was detected. The monoclonal antibody
6F/3D showed temperature-dependent reactivity, and the
reactivity was bimodal; decreasing and increasing reactivity of
0.5 and 0.4 absorbance units, respectively, when the modified
temperature was increased from 36 to 38°C, and from 38 to
41°C respectively. On the other hand, 4G8 showed
temperature-dependent reactivity; apparent decreased reac-
tivity of 0.6 absorbance units when the temperature was
increased from 36 to 40°C. No significant difference was
detected between 6F/3D and 4G8. Thus, the 9–14 and 17–21
amino acid residues within the Ab40 peptide were sensitive to
temperature changes.
Inhibition of temperature-modified conformational changes of
Ab40 by bSBP
The preliminary study indicated that Ab1–16 did not change
the reactivity of Ab40,whereas a change was evident for
Ab17–42 (data not shown). According to the present results
shown in Figure 1, we investigated the reactivity of 6F/3D
antibody towards the mixture of temperature-modified Ab40
with bSBP 15–22, 16–23, 17–24 or 18–25. We chose 6F/3D,
which recognized 9–14 of Ab40, to avoid direct interaction
with the bSBPs, because 4G8 recognized 17–21 of Ab40 which
includes the sequences of the bSBPs. The reactivity of Ab40
alone was regarded as control. The bSBP 15–22 (Figure 2A)
and 18–25 (Figure 2D) did not change the reactivity of Ab40;
however, bSBP 16–23 (Figure 2B) and 17–24 (Figure 2C) could
change the reactivity of Ab40 in a constant manner. In the
present study, the molar ratio of Ab40 to the bSBPs was 1:5,
and a lower ratio of bSBPs to Ab40 was not effective; however,
higher ratios showed almost the same effects as those with the
1:5 molar ratio (data not shown). We repeated these assays
using bSBPs made up in 0.4 M NaOH and adjusted to pH 7,
the same conditions as in the CD studies, and measured the
changes of antibody affinity towards temperature-modified
Ab40. The signals from Ab40 with the bSBPs prepared in
DMSO were almost the same as those with the bSBPs prepared
in NaOH, and the immunoreactivity patterns were similar to
each other (data not shown).
Effect of bSBPs on temperature-induced conformational changes
of Ab40 in the presence and absence of PK
The amount of protein remaining on the membrane before
and after PK digestion at three different temperatures 36, 38
and 42°C, and at 20°C as a soluble Ab40 control is shown in
Figure 3A as a representative result of six experiments. The
soluble control showed remarkable differences before and
after PK digestion. No significant effect was detected for tem-
peratures within each bSBP group; however, the spot density
was lower in the presence of bSBPs 16–23 and 17–24 after PK
digestion than Ab40 alone with PK, indicating the effects of
these bSBPs were to increase Ab40 sensitivity to PK digestion.
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Figure 2 Changes of antibody affinity towards temperature-modified Ab40 in the presence of b-sheet breaker peptides (bSBPs). The reactivity
of 6F/3D was determined by enzyme-linked immunosorbent assay for temperature-modified Ab40 without bSBP () and with relevant bSBP
( ): 15–22 (A), 16–23 (B), 17–24(C) and 18–25(D). Statistical comparisons were made with unpaired t-tests. The values are means  SEM.
Statistically significant differences versus Ab40 alone were determined at each temperature. *P < 0.05, ***P < 0.001 (n = 6).
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in Figure 3A. In this study, the PK digestion showed a ten-
dency to reduce Ab40 spot density (30%), but this was not
significant, and bSBPs 15–22 and 18–25 did not alter the spot
density level either. On the other hand, the bSBPs 16–23 and
17–24 reduced the spot densities by around 80% after PK
digestion, indicating greater digestion with PK of Ab40 and
higher PK sensitivity in the presence of the two bSBPs. The
spots of Ab40 with/without DMSO before and after PK diges-
tion showed no differences, indicating DMSO at this concen-
tration did not affect the results. These results are also
comparable with the results of the ELISA. In the present study,
we also tested various molar ratios of Ab40 to the bSBPs at 1:1,
1:5, 1:10 and 1:20 for PK digestion, and observed no altered
PK sensitivity below the molar ratio of 1:5.
CD spectra of Ab40 with bSBPs
The CD experiments were carried out to confirm the effects of
bSBPs to prevent temperature-induced conformational
changes of Ab40 at 38°C (Figure 4). The minimum CD spec-
trum of Ab40 alone was at around 218 nm, which corre-
sponds to a b-sheet-rich conformation. Although the
minimum CD spectrum of Ab40 with bSBP 15–22 was not
shifted, the spectra of Ab40 with bSBP 16–23, 17–24 and
BA
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Figure 3 Determination of protease K (PK) sensitivity for temperature-modified Ab40 in the presence of b-sheet breaker peptides (bSBPs) by
dot blot. Effects of bSBPs 15–22, 16–23, 17–24 and 18–25 on PK-induced digestion of temperature-modified Ab40 at 36, 38, 42°C and at 20°C
as a control were determined by dot blot. (A) Each spot shows the remaining Ab40 without or with PK, and the figure is a representative of
six experiments. (B) The average pixel density of each spot at 38°C was measured by NIH image analysis after subtracting the mean
background pixel density from that of the spots. Values are means  SEM. Statistical analysis was performed with analysis of variance and
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Figure 4 Circular dichroism (CD) spectra reveal the reduction of thermally induced b-sheet formation of Ab40 at 38°C with b-sheet breaker
peptide (bSBP). The secondary structure of thermally induced Ab40 at 38°C, and at 20°C as a control in the presence or absence of bSBP was
measured by far-UV CD spectra. Spectra for Ab40 alone (sBP) as a control, and mixtures with bSBP 15–22, 16–23, 17–24 and 18–25 are shown.
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18–25 were shifted to around 200 nm, which was close to the
soluble control Ab40 at 20°C. In addition, the CD amplitudes
at 218 nm of Ab40 with bSBP 16–23, 17–24 and 18–25 were
increased more than the values for Ab40 alone by 3.9–
5.8 mdeg. These results indicate that all bSBPs except 15–22
could inhibit b-sheet formation of Ab40 at 38°C.
Discussion
It is generally accepted that the conformational changes
within the Ab protein that result in aggregation of aberrant
b-sheet-rich intermediates, are important in the development
of AD. Determination of the sequences within Ab that are
involved in these changes, and inhibition of such changes by
bSBPs have considerable potential for a novel therapeutic
approach to AD.
The conformational changes are induced by thermody-
namic stress (Sengupta et al., 2003). However, various physi-
ological factors including pH shift, co-precipitants of metal
ions (Atwood et al., 1998) and abnormal oxidative metabo-
lites including cholesterol-derived aldehydes (Bieschke et al.,
2005) are also involved in the conformational changes of
Ab40 in brain.
High temperature (including fever) could induce structural
changes in Ab (tangles and plaques) or changes in brain
similar to those observed in AD (Sinigaglia-Coimbra et al.,
2002). Our preliminary experiments revealed that when a
wide range of temperatures (0–99°C) was applied, the confor-
mation of Ab40 at 0–20°C was (a-helical, whereas conforma-
tional changes of Ab40 towards b-sheet configuration were
observed at 35–45, 60–65 and 80–85°C. The occurrence of
changes within specific temperature ranges may indicate
thermal specificity or the adoption by Ab40 of various
conformations at wide range of heating, due to increasing
intermolecular b-sheet structures (Chu and Lin, 2001).
We chose to work over 35–42°C, a temperature range that
includes the physiological limits, and found that the apparent
changes at 36–38°C involved the epitopes around amino acid
residues 9–14, whereas the changes induced at 36–40°C
involved those around residues 17–21. We infer from these
results that the 6F/3D epitope (amino acid residues 9–14) in
Ab40 was inaccessible at 38°C, and again exposed at around
41°C; however, that of the 4G8 epitope was inaccessible over
38°C. Both sequences have been reported to be involved in
pH-induced conformational transitions of Ab42 (Matsunaga
et al., 2002). However, CD spectra study for thermally modi-
fied Ab40 at 36–40°C lacks conformational changes (data not
shown), indicating retention of the secondary structure and
only a minor loosening of the tertiary structure, within this
temperature range.
Various terminuses and segments of Ab40 may display dif-
ferent biophysical properties and biological activities. The
C-terminus of Ab40 quiescent fibrils lacks b-sheet structure
compared to the more rigid structure within the 24–30
segment (Williams et al., 2006). It seems that the thermal
changes take place in a part of Ab40 involving the central
hydrophobic region that is also implicated in various biologi-
cal functions including interaction with other proteins
(Golabek et al., 1996). Moreover, the 9–21 sequence includes
amino acid residues 10–23 that provide the structural basis of
the hydrophobic behaviour under physiological conditions
(Hilbich et al., 1991).
It has been reported that the pentapeptides bSBP KLVFF
(16–20) and LPFFD (17–21 analogous) interact with the main
Ab structure via hydrogen bridges with the bSBP binding in
the plane of the amyloid dimer (Hetenyi et al., 2002). The
present results from ELISA and dot blot studies showed that
temperature-induced conformational changes were reversed
by octapeptide bSBPs 16–23 and 17–24, but not by bSBPs
15–22 and 18–25.
As the bSBPs are not water soluble, we could not avoid the
use of DMSO, NaOH being the alternative for dissolving the
bSBPs. The use of DMSO may alter Ab40 conformation;
however, a pH shift by NaOH may have a greater effect on
Ab40 behaviour (Matsunaga et al., 2002). In the present study,
we used minimal amount of DMSO to dissolve the bSBPs, and
diluted with water to the final DMSO concentration of 0.2%
(Figures 2 and 3), which did not affect the conformation of
Ab40 (Shen and Murphy, 1995; Kanaoka et al., 2003), but this
concentration is high enough to change the cell membranes
and induce heat shock proteins in biological experiments.
However, as traces of DMSO disturb the CD spectra, we used
0.4 M NaOH instead of DMSO to dissolve the bSBPs and
adjusted to pH 7. The effect of bSBP 18–25 revealed by CD
study did not correspond to the results of ELISA and dot blot
(Figure 4). We speculate that incubation of Ab40 with pure
water and a pH shift by NaOH to dissolve the bSBPs in the CD
study may be responsible for the different results of bSBP
18–25 between ELISA, dot blot and CD studies.
The region 16–23 (KLVFFAED) used in this study contains
KLVFF that has been reported to protect against Ab toxicity
(Pallitto et al., 1999). Moreover, it has been proposed that the
region 1–16 is not active by itself, but is required for the
activity of Ab40, whereas the region 29–42 is inactive in
pH-induced conformational changes (Matsunaga et al., 2004).
From the results obtained in this study, we suggest that the
amino acid residues 16–24 within Ab40 is the region that is
involved in reversal of temperature-dependent conforma-
tional changes by the bSBPs. However, our studies showed
that the bSBPs 16–23 and 17–24 prevented the temperature-
dependent conformational changes of Ab40.
Our results also showed that bSBP 16–23 and 17–24 exposed
Ab40 to the activity of PK, as PK did not affect the already
denatured Ab40, but could digest it in the presence of bSBPs
16–23 and 17–24, but not the bSBPs 15–22 and 18–25. The
ability of partial Ab fragments around Ab 16–23 to inhibit
Ab40 aggregation may be due to their ability to bind the
central hydrophobic region of Ab40 including the
temperature-sensitive region, thereby destabilizing oligomers
necessary for fibril stability. As a result, the site of protease
cleavage would be exposed to the activity of PK. However,
the bSBP 15–22 besides not inhibiting temperature-
conformational changes, did not reduce PK digestion.
In conclusion, our results revealed that Ab40 exhibited dif-
ferential temperature-dependent conformational changes:
the epitopes 9–14 involved in the conformational change
induced at 36–38°C, whereas epitope 17–21 involved in those
induced at 36–40°C. These changes could be reversed by the
bSBPs 16–23 and 17–24. These bSBPs could be of value in the
bSBPs inhibit thermal-sensitive regions of Ab40
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treatment of AD, and in vivo studies are required to confirm
the possible therapeutic value of the compounds.
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